CXCL16 Stimulates Antigen-Induced MAIT Cell Accumulation but Trafficking During Lung Infection Is CXCR6-Independent

Huiwen Yu¹, Amy Yang¹, Ligong Liu²,³, Jeffrey Y. W. Mak²,³, David P. Fairlie²,³ and Siobhan Cowley*¹

¹Laboratory of Mucosal Pathogens and Cellular Immunology, Division of Bacterial Parasitic and Allergic Products, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, United States, ²Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia, ³Australian Research Council Centre of Excellence in Advanced Molecular Imaging, The University of Queensland, Brisbane, QLD, Australia

Mucosa-associated invariant T (MAIT) cells are a unique T cell subset that contributes to protective immunity against microbial pathogens, but little is known about the role of chemokines in recruiting MAIT cells to the site of infection. Pulmonary infection with Francisella tularensis live vaccine strain (LVS) stimulates the accrual of large numbers of MAIT cells in the lungs of mice. Using this infection model, we find that MAIT cells are predominantly CXCR6⁺ but do not require CXCR6 for accumulation in the lungs. However, CXCR6 does contribute to long-term retention of MAIT cells in the airway lumen after clearance of the infection. We also find that MAIT cells are not recruited from secondary lymphoid organs and largely proliferate in situ in the lungs after infection. Nevertheless, the only known ligand for CXCR6, CXCL16, is sufficient to drive MAIT cell accumulation in the lungs in the absence of infection when administered in combination with the MAIT cell antigen 5-OP-RU. Overall, this new data advances the understanding of mechanisms that facilitate MAIT cell accumulation and retention in the lungs.

Keywords: MAIT cells, pulmonary infection, F. tularensis, CXCR6, CXCL16

INTRODUCTION

Mucosa-associated invariant T (MAIT) cells are innate-like T cells that play important roles in protective immunity against microbial infections (1–5). MAIT cells are activated by riboflavin-related metabolites presented by the major histocompatibility complex (MHC) class I related protein (MR1). Riboflavin-related metabolites such as 5-(2-oxopropylideneamino)-6-D-ribitylaminouracil (5-OP-RU) are present in many bacteria, yeast, and plants, but not in mammals and other animals (6–8). Several pathogens such as Francisella tularensis live vaccine strain (LVS), Legionella longbeachae, and Salmonella typhimurium BRD509 have been reported to activate MAIT cells in vivo (9–11). MAIT cells have been implicated in anti-tumor responses and the exacerbation/amelioration of autoimmune diseases, including diabetes I, multiple sclerosis and gut-associated diseases like colitis (12–14).

Chemokines are differentially expressed in different tissues and inflammatory microenvironments and guide the homing of specific leukocyte subsets via interactions with differential cell surface chemokine receptors (15–17). Chemokines play critical roles in immunity...
and inflammation, including immune system development, leukocyte positioning, lymphocyte migration, and phagocyte activation (15, 18, 19). These important proteins and their receptors have been targeted as clinical therapies and investigated as biomarkers for certain human diseases (19).

In humans, MAIT cells have been observed in numerous tissues, including the lungs, intestinal lamina propria, liver, and peripheral blood (20–23). Human peripheral blood MAIT cells exhibited high levels of CCR6 and CXCR6, heterogenous levels of CXCR4, and intermediate expression of CCR9 under steady-state conditions, which may reflect the potential for circulating MAIT cells traffic to different tissues (21). Indeed, numerous reports have noted a significant decrease in the number of MAIT cells present in the peripheral blood of patients during infections, suggesting their recruitment from the blood to the site of infection. In contrast, MAIT cells in naïve pathogen-free wild type mice were present in low numbers in most tissues (24, 25), including the blood (0.09% of total CD3+ T cells). Nevertheless, MAIT cells in the lungs of naïve mice were largely positive for CCR6 and low for CCR9 (25).

Little is known about the role of chemokines and their receptors in regulating MAIT cell localization in tissues. It is unclear whether MAIT cells are recruited from peripheral tissues and local lymph nodes during inflammation, or whether they largely proliferate in situ at the site of infection. Since our previous work showed that MAIT cells robustly accumulated in the lungs of mice during pulmonary *F. tularensis* LVS infection, we used this model to investigate the role of proliferation and chemokine recruitment in MAIT cell expansion in the lungs after infection (1, 9). Here we find that, despite being predominantly CXCR6+, MAIT cells do not require CXCR6 for accumulation at the site of infection. We further find that MAIT cell accumulation is not driven by recruitment from secondary lymphoid organs, and that the majority of MAIT cells proliferate in situ in the lungs after pulmonary *F. tularensis* LVS infection. Surprisingly, however, the only known ligand for CXCR6, CXCL16, was sufficient to drive MAIT cell accumulation in the lungs of naïve mice when administered intranasally with the MAIT cell antigen 5-OP-RU (26).

**MATERIALS AND METHODS**

**Mice and Infection**

*F. tularensis* LVS (ATCC) was grown and frozen as previously described (27). MR1 KO mice (28) and Vα19/1TgCa2+−/− MR1+/+ transgenic mice exclusively expressing the canonical TCR Vα19- Jα33 of mouse MAIT cells (29) were obtained from Ted Hansen (Washington University in St. Louis, St. Louis, MO) and bred at CBER/FDA. Wild type mice (C57BL6j #000664) and CXCR6+/- mice (#005693) were purchased from The Jackson Laboratory. Animals were housed in a barrier environment at CBER/FDA, and procedures were performed according to approved protocols under the FDA Animal Care and Use Committee guidelines. Bacteria were diluted in PBS (Gibco, Life Technologies), and intranasal (IN) infections were performed by delivering 1 or 2 × 105 LVS colony-forming units (CFU) in a volume of 25 µl to anesthetized mice.

For *in vivo* MAIT cell induction therapy, the first dose consisted of a combination of 30 µg Pam3CSK4 (Invivogen) and MAIT cell ligands (5-OP-RU or Ac-6-FP, 37.5 µl of an 8 µM solution) administrated IN per mouse. The second and third doses consisted of 5-OP-RU or Ac-6-FP (37.5 µl of a 4 µM solution) administrated IN per mouse. For MAIT cell induction therapies using chemokines, the relevant recombinant chemokines (CXCL16, heat-denatured CXCL16, and CCL24) were administered in the following regimen: the first dose consisted of a combination of 3 µg chemokine and MAIT cell ligands (5-OP-RU or Ac-6-FP, 37.5 µl of an 8 µM solution) administrated IN per mouse. The second and third doses consisted of 3 µg chemokine and 5-OP-RU or Ac-6-FP (37.5 µl of a 4 µM solution) administrated IN per mouse. CXCL16 and CCL24 were purchased from R&D systems. CXCL16 was heat-denatured by incubation at 100°C for 10 min. In all cases, lungs were harvested and processed for flow cytometry analyses 6 days after the first dose.

For FTY720 (Sigma) treatment, mice were injected daily i.p. with 0.5 mg/kg/day of FTY720 dissolved in sterile PBS after day 2 of LVS IN infection. Untreated control mice received an equivalent volume of sterile PBS. For BrdU treatment, mice were administered BrdU (62.5 µl of 10 mg/ml of BrdU) IN daily on days 6–9 after infection. BrdU staining was performed according to the manufacturer’s instructions (BD).

**Preparation of Synthetic Ligands**

Synthetic 5-OP-RU (as a DMSO solution) and Ac-6-FP were prepared according to previously published procedures (26, 30).

**Preparation of Single-Cell Suspensions**

To prepare lung cells for flow cytometry, the lungs were excised and transferred to a Petri dish and chopped with a sharp scissors for ~30 s, or until no large pieces were visible. The pieces should be small enough to pass through 10 ml serological pipettes. The lung pieces were incubated with 3 ml of DMEM containing 10% FBS, collagenase D and MAIT cell ligands (5-OP-RU or Ac-6-FP, 37.5 µl of an 8 µM solution) administrated IN per mouse. CXCL16 and CCL24 were purchased from R&D systems. CXCL16 was heat-denatured by incubation at 100°C for 10 min. In all cases, lungs were harvested and processed for flow cytometry analyses 6 days after the first dose. For FTY720 (Sigma) treatment, mice were injected daily i.p. with 0.5 mg/kg/day of FTY720 dissolved in sterile PBS after day 2 of LVS IN infection. Untreated control mice received an equivalent volume of sterile PBS. For BrdU treatment, mice were administered BrdU (62.5 µl of 10 mg/ml of BrdU) IN daily on days 6–9 after infection. BrdU staining was performed according to the manufacturer’s instructions (BD).

**Preparation of Synthetic Ligands**

Synthetic 5-OP-RU (as a DMSO solution) and Ac-6-FP were prepared according to previously published procedures (26, 30).

**Preparation of Single-Cell Suspensions**

To prepare lung cells for flow cytometry, the lungs were excised and transferred to a Petri dish and chopped with a sharp scissors for ~30 s, or until no large pieces were visible. The pieces should be small enough to pass through 10 ml serological pipettes. The lung pieces were incubated with 3 ml of DMEM containing 10% FBS, collagenase D and MAIT cell ligands (5-OP-RU or Ac-6-FP, 37.5 µl of an 8 µM solution) administrated IN per mouse. CXCL16 and CCL24 were purchased from R&D systems. CXCL16 was heat-denatured by incubation at 100°C for 10 min. In all cases, lungs were harvested and processed for flow cytometry analyses 6 days after the first dose. For FTY720 (Sigma) treatment, mice were injected daily i.p. with 0.5 mg/kg/day of FTY720 dissolved in sterile PBS after day 2 of LVS IN infection. Untreated control mice received an equivalent volume of sterile PBS. For BrdU treatment, mice were administered BrdU (62.5 µl of 10 mg/ml of BrdU) IN daily on days 6–9 after infection. BrdU staining was performed according to the manufacturer’s instructions (BD).

**Preparation of Synthetic Ligands**

Synthetic 5-OP-RU (as a DMSO solution) and Ac-6-FP were prepared according to previously published procedures (26, 30).

**Preparation of Single-Cell Suspensions**

To prepare lung cells for flow cytometry, the lungs were excised and transferred to a Petri dish and chopped with a sharp scissors for ~30 s, or until no large pieces were visible. The pieces should be small enough to pass through 10 ml serological pipettes. The lung pieces were incubated with 3 ml of DMEM containing 10% FBS, collagenase D and MAIT cell ligands (5-OP-RU or Ac-6-FP, 37.5 µl of an 8 µM solution) administrated IN per mouse. CXCL16 and CCL24 were purchased from R&D systems. CXCL16 was heat-denatured by incubation at 100°C for 10 min. In all cases, lungs were harvested and processed for flow cytometry analyses 6 days after the first dose. For FTY720 (Sigma) treatment, mice were injected daily i.p. with 0.5 mg/kg/day of FTY720 dissolved in sterile PBS after day 2 of LVS IN infection. Untreated control mice received an equivalent volume of sterile PBS. For BrdU treatment, mice were administered BrdU (62.5 µl of 10 mg/ml of BrdU) IN daily on days 6–9 after infection. BrdU staining was performed according to the manufacturer’s instructions (BD).
In vitro Bone Marrow-Derived Macrophage Co-cultures

BMMØ were cultured as previously described. Briefly, bone marrow was flushed from femurs of healthy wild type mice with Dulbecco minimal essential medium (DMEM; Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (FCS; HyClone), 10% L-929 conditioned medium, 0.2 mM L-glutamine (Life Technologies), 1 mM HEPES buffer (Life Technologies), and 0.1 mM non-essential amino acids (Life Technologies) [complete DMEM (cDMEM)]. Cells were washed, a single cell suspension prepared, and cells plated at 1 × 10^6 in 48-well plates, or 2 × 10^6 in 24-well plates, in cDMEM supplemented with 50 µg/ml gentamycin (Life Technologies) and incubated at 37°C in 5% CO₂. After 1 day of incubation, the medium was replaced with antibiotic-free cDMEM, and the cells were incubated for an additional 6 days at 37°C in 5% CO₂. The medium was replaced with fresh, gentamycin-free cDMEM every 2 days during the 7-day incubation. Va19iTgCa^-/- MR1^+/+ mice were used as source of MAIT cells for co-culture with BMMØs. Total Thy1.2+ T cells were purified from Va19iTgCa^-/- MR1^+/+ mouse spleens using a Thy1.2+ cell enrichment column (Life Technologies), according to the manufacturer’s recommendations. MAIT cells were added to the wells at a ratio of 1 T cell to 2 macrophages. Recombinant CXCL16 (200 ng/ml) and 5-OP-RU (9.3 µM) were added to the cultures at the same time as the MAIT cells, and supernatants were collected for cytokine analyses (ThermoFisher Luminex assay for Cytokine & chemokine 26-Plex Mouse ProcartaPlex™ Panel 1) 16 h later.

Flow Cytometry Analyses and Intracellular Cytokine Staining

Cells were stained for a panel of murine cell surface markers and analyzed by using a BD LSR Fortessa flow cytometer and FlowJo software. Ab clones used included GK1.5 (anti-CD4), 53-6.7 (anti-CD8α), H57-597 (anti-TCR β-chain), MP6-XT22 (anti-TNFα), TC1118H10.1 (anti-IL17A), XMG1.2 (anti-IFN-γ), 2E7 (anti-CD103), M1/70 (anti-CD11b), 2G12 (anti-CR4), HM-CR5 (anti-CR5), 29-2L17 (anti-CR6), CXCR3-173 (anti-CXCR3), DATK32 (anti-α4β7), 2E7 (anti-CR9), SA051D1 (anti-CXCR4), SA203G11 (anti-CR2), J073E5 (anti-CR3), CXCR3-173 (anti-CXCR3), 4B12 (anti-CR7), SA051D1 (anti-CXCR6) were obtained from BioLegend. MR1 tetramers were obtained from the National Institutes of Health Tetramer Core Facility (Atlanta, GA). Live/Dead Near IR stain (Molecular Probes) was included in all staining protocols. Optimal antibody concentrations were determined in separate experiments, and appropriate fluorochrome-labeled isotype control antibodies or “fluorescence minus one” (FMO) controls were used throughout. In all cases, cells were first gated on singlets (forward scatter-width or forward scatter-area vs. -height) and live cells (Live/Dead Near IR negative) before further analyses. To monitor the expression of TNF, IFN-γ, and IL-17A, lung cells were incubated in complete Dulbecco’s modified eagle medium (cDMEM) containing 5 µg/mL Brefeldin A at 37°C in 5% CO₂ for 4 h in the presence or absence of PMA and ionomycin. Cells were stained for cell surface markers and followed by intracellular staining. Intracellular staining was performed by using the BD Biosciences buffer system according to the manufacturer’s instructions.

Quantitation of CXCL16 in Lung Homogenates

The left side of the lung from each mouse was homogenized in 500 µl of T-PER™ tissue protein extraction reagent (ThermoFisher Scientific) containing proteinase inhibitor using a FastPrep-24™ 5G Instrument (MP Biomedicals). The lung homogenates were assayed using the mouse CXCL16 ELISA kit (ThermoFisher Scientific) according to the manufacturer’s instructions.

Statistical Analyses

All experiments were performed and repeated at least two to three time to assess reproducibility using three to five mice per experimental group unless otherwise stated in the figure legend. Data are represented as mean ± SEM and data were analyzed via one-way ANOVA followed by the Student-Newman-Keuls multiple stepwise comparison (for experiments with >2 experimental groups). A P <0.05 was considered a significant difference (∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001).

RESULTS

Lung MAIT Cells Are Predominantly CXCR6+ During Pulmonary F. tularensis LVS Infection

To identify important chemokine receptors that may be used by MAIT cells for homing during infection, we first sought to characterize MAIT cell surface expression of different chemokine receptors during steady state and infectious conditions. Previous studies have shown that MAIT cell numbers in naïve pathogen-free wild type (WT) C57BL/6 mice are exceptionally low, constituting <0.2% of cells in the lungs, spleen, and thymus (24). In order to reliably assess the expression of chemokine receptors by MAIT cells under steady state conditions, we utilized transgenic mice that exclusively express the canonical MAIT cell Vα19-Jo33 TCRα chain (Vα19iTg mice). The gating strategy used to identify MAIT cells is shown in Figure S1. As expected, naïve Vα19iTg mice had high levels of MAIT cells in their lungs (7.8%), spleen (5.7%), thymus (3.3%), and lamina propria (0.2% vs. 9.1 ± 0.01 × 10⁶ naïve Vα19iTg mice). The gating strategy used to identify MAIT cells is shown in Figure S1. As expected, naïve Vα19iTg mice had high levels of MAIT cells in their lungs (7.8%), spleen (5.7%), thymus (3.3%), and lamina propria (0.2% vs. 9.1 ± 0.01 × 10⁶ naïve Vα19iTg mice). The gating strategy used to identify MAIT cells is shown in Figure S1. As expected, naïve Vα19iTg mice had high levels of MAIT cells in their lungs (7.8%), spleen (5.7%), thymus (3.3%), and lamina propria (0.2% vs. 9.1 ± 0.01 × 10⁶ naïve Vα19iTg mice). The gating strategy used to identify MAIT cells is shown in Figure S1. As expected, naïve Vα19iTg mice had high levels of MAIT cells in their lungs (7.8%), spleen (5.7%), thymus (3.3%), and lamina propria (0.2% vs. 9.1 ± 0.01 × 10⁶ naïve Vα19iTg mice). The gating strategy used to identify MAIT cells is shown in Figure S1. As expected, naïve Vα19iTg mice had high levels of MAIT cells in their lungs (7.8%), spleen (5.7%), thymus (3.3%), and lamina propria (0.2% vs. 9.1 ± 0.01 × 10⁶ naïve Vα19iTg mice).
FIGURE 1 | MAIT cells in the lungs of Vα19Tg mice predominantly express the chemokine receptor CXCR6 during F. tularensis LVS intranasal infection. (A) Representative flow cytometry dot plots of MAIT cells in the lungs, spleen (Spl), thymus (Thy), and intestinal lamina propria (LP) of naïve Vα19Tg mice (upper panel)
examined, only CXCR6 exhibited a significant change in the level of cell surface expression on MAIT cells in the lungs 14 days after LVS IN infection. As shown in Figure 1C, the percentage of CXCR6-expressing MAIT cells in the lungs increased almost five-fold in infected Vα19Itg mice (79.4% ± 1.7) as compared to naïve Vα19Itg mice (18.4% ± 3.0). A small but significant increase in the levels of CXCR6-expressing MAIT cells was also observed in the spleen, but not the thymus and LP after infection (Figures 1D,F). We found that relatively few MAIT cells expressed CCR2, CCR4, CCR6, CXCR3, CXCR4, and CCR9 in the lungs (Figure 1C), spleen (Figure 1D), thymus (Figure 1E), and LP (Figure 1F) both before and after infection. Of those chemokine receptors, only a slight increase in the percentage of CXCR3-expressing MAIT cells was observed after infection, and this only occurred in the thymus (P < 0.05). In addition, the mucosal integrin CD103 was expressed by about 20% of MAIT cells in the lung, spleen, thymus, and LP, but these levels did not significantly change following LVS IN infection.

We next sought to determine whether MAIT cells exhibit a similar pattern of chemokine receptor expression in WT C57BL/6 mice during F. tularensis LVS IN infection. Fourteen days after LVS IN infection, large numbers of MAIT cells were observed in the lungs (9.1% ± 2.0), while relatively few were found in the spleen (0.9% ± 0.1), LP (0.5% ± 0.1), and thymus (0.2% ± 0.05; Figure 2A). Because such low numbers of MAIT cells were present in the LP and thymus, we did not examine chemokine receptor expression in these tissues. Consistent with our observations in LVS-infected Vα19Itg mice, MAIT cells in the lungs of infected WT mice were predominantly CXCR6+ (~80%; Figures 2B,C; controls are shown in Figure S2). In the spleen, ~60% of MAIT cells expressed CXCR6 and 20% expressed CCR6 (Figure 2C). Thus, a large proportion of MAIT cells in the lungs express the chemokine receptor CXCR6 during pulmonary LVS infection, suggesting that this receptor may participate in MAIT cell trafficking to the lungs.

The CXCR6 Ligand CXCL16 Is Up-Regulated in the Lungs During Pulmonary F. tularensis LVS Infection

The only known ligand for CXCR6 is CXCL16, which was previously found to be expressed at high levels in the liver and lungs of naïve mice (32–34). Since the vast majority of MAIT cells responding to LVS pulmonary infection in the lungs were CXCR6+, we next investigated whether CXCL16 is elevated in the lungs during pulmonary LVS infection. To this end, we gave WT mice a sublethal LVS IN infection and CXCL16 levels were assessed in the lungs over time. As shown in Figure 2D, approximately 2 ng/ml of CXCL16 was detected in the lungs of naïve WT mice. The levels of CXCL16 significantly increased as early as 4 days after LVS IN infection and peaked 7–10 days post-infection (an approximately five-fold increase as compared to naïve mice on day 10; P < 0.001). By 21 days after LVS infection, at a time when bacterial CFUs were fully cleared, the CXCL16 levels had diminished but not fully returned to that of naïve mice (P < 0.05). Thus, CXCL16 is significantly up-regulated in the lungs during LVS pulmonary infection and may serve as a mechanism to recruit CXCR6-expressing MAIT cells.

CXCR6 Is Not Required for MAIT Cell Accumulation in the Airway Lumen and Lung Parenchyma During Pulmonary F. tularensis LVS Infection

To further elucidate the role of CXCR6 in MAIT cell localization and function during infection, we compared MAIT cell accumulation in the lungs of CXCR6 knock out mice (CXCR6−/−) and WT mice after LVS IN infection. We previously found that MAIT cell numbers increased substantially after the first week of LVS pulmonary infection (days 8–9), reached a peak during the clearance phase of infection (days 10–14), and declined slowly thereafter but remained a notable presence in the lungs for a long time (>56 days) (9). Thus we examined MAIT cell accumulation in the lungs of CXCR6−/− and WT mice on days 10 and 54 after LVS IN infection. In addition, since recent research reported that the CXCR6/CXCL16 signaling axis regulated localization of tissue resident memory CD103+ CD69+ CD8+ T cells to the airway lumen (35), we examined MAIT cell partitioning in the lungs by assessing MAIT cell numbers in the lung parenchyma and airway lumen (BAL fluid). There were no differences in the total numbers of MAIT cells in the lung parenchyma (Figure 3A) and airway lumen (Figure 3B) on day 10. However, MAIT cell numbers in the airway lumen, but not the lung parenchyma, were significantly reduced in CXCR6−/− mice as compared to WT mice on day 54, long after clearance of the LVS infection (at approximately day 18). Of note, we observed no significant differences in LVS growth in the lungs between WT and CXCR6−/− mice (Figure S2). MAIT cell numbers in the spleen were not significantly different between LVS-infected WT and CXCR6−/− mice at a time when MAIT cell numbers peaked in that tissue (day 14) (Figure 3C). Overall, these data show that CXCR6 is not essential for MAIT cell accumulation in the lungs and spleen during LVS IN infection but has a significant role in maintaining MAIT cells in the airway lumen long after clearance of the infection.

Previous studies have shown that the loss of CXCR3 expression by MAIT cells in patients with end stage renal disease was coupled to increased expression of CCR6 and CXCR6 (36).
FIGURE 2 | MAIT cells in the lungs of WT mice predominantly express the chemokine receptor CXCR6 during F. tularensis LVS intranasal infection. (A) Flow cytometry analysis of MAIT cells in the lungs, Spl (spleen), Thy (thymus), and LP (lamina propria) of LVS-infected WT mice on day 14 after LVS infection, showing reactivity to MR1-5-OP-RU tetramer in total lung cells. (B) Representative flow cytometry dot plots depicting expression of different chemokine receptors on MAIT cells in LVS-infected WT mice lungs (day 14 after infection). Plots show live 5-OP-RU MR1 tetramer+ TCRβ+ cells. (C) A graphical representation of the percentage of MAIT cells positive for the indicated chemokine receptors in the lungs and spleens (Spl) of LVS-infected WT mice on day 14 after infection. (D) The levels of CXCL16 in lung homogenates of naïve and LVS-infected WT mice at the indicated time points (*P < 0.05; **P < 0.001 as compared to naïve Day 0 mice). Data are presented as the mean ± SEM (n = 5–6) and are representative of two independent experiments.
CXCR6 is not required for MAIT cell accumulation in the lung parenchyma or spleen during F. tularensis LVS intranasal infection but contributes to long-term retention in the airway lumen (BAL). (A) Representative flow cytometry dot plots showing the percentage of MAIT cells in the lung parenchyma of WT and CXCR6−/− mice. (B) Airway lumen. (C) Spleen. (D) Cytokine-positive MAIT cells in WT and CXCR6−/− LVS infected mice.
To assess the possibility that other chemokine receptors may have compensated for the loss of CXCR6 in the CXCR6\(^{-/-}\) mice, we examined the cell surface expression of a panel of chemokine receptors on MAIT cells present in the lungs of infected WT mice and CXCR6\(^{-/-}\) mice. No significant changes were observed in the proportion of MAIT cells expressing the chemokine receptors CCR2, CCR4, CCR5, CCR6, CCR9, CXCR3, CXCR4, and CXCR6 in LVS-infected CXCR6\(^{-/-}\) mice as compared to WT mice (data not shown). Thus, our evidence suggests that MAIT cell accumulation in the lungs of CXCR6\(^{-/-}\) mice is not the result of compensation via any of the aforementioned chemokine receptors.

Although we were unable to detect a difference in the number of MAIT cells present in the lungs of WT and CXCR6\(^{-/-}\) mice after LVS IN infection, it was possible that the MAIT cells accumulating in the lungs of the CXCR6\(^{-/-}\) mice had functional deficits. To this end, we compared cytokine production by MAIT cells in the lungs of LVS-infected WT and CXCR6\(^{-/-}\) mice. No significant differences were observed in the production of IL-17, IFN-\(\gamma\), or TNF by MAIT cells obtained from the lungs of LVS-infected WT and CXCR6\(^{-/-}\) mice (data not shown). Similarly, no differences in cytokine production were detected by MAIT cells obtained from the same mice and further stimulated \textit{ex vivo} with PMA/ionomycin (Figure 3D). Thus, MAIT cells from CXCR6\(^{-/-}\) mice do not have obvious deficits in IL-17, IFN-\(\gamma\) or TNF production.

### The Majority of MAIT Cells Proliferate in the Lungs During Pulmonary \textit{F. tularensis} LVS Infection

Since we were unable to identify any chemokine receptors that were likely to promote MAIT cell recruitment to the lungs during LVS infection, we next determined whether MAIT cells proliferated in the lungs during pulmonary LVS infection. As shown in Figure 4A, MAIT cell numbers in the lungs increased significantly starting on day 6 after LVS infection as compared to naïve mice. To determine whether this increase was the result of MAIT cell recruitment to the site of infection or \textit{in situ} proliferation in the lungs, MAIT cells present in the lungs were given the opportunity to incorporate bromodeoxyuridine (BrdU) delivered via the IN route. BrdU is a synthetic nucleoside analog of thymidine that is only incorporated into actively replicating cells. BrdU was administered daily days 6–9 after infection, and BrdU\(^{+}\) MAIT cells were assessed in the lungs on day 10. Approximately 60% of MAIT cells were BrdU\(^{+}\) on day 10 after infection (Figure 4B), indicating that the majority of these cells had proliferated in the preceding 4 days.

Since previous studies showed that some of the BrdU delivered IN to mice travels to the lung-draining lymph nodes (37), it remained possible that some of the BrdU\(^{+}\) MAIT cells observed in the lungs had migrated from local lymph nodes. To address this possibility, we first examined the MAIT cell population in the mediastinal and cervical lymph nodes on day 10 after LVS IN infection. Although MAIT\(^{+}\) cells were a very small population in the lung-draining lymph nodes (Figure 4C), a significant proportion of these cells were BrdU\(^{+}\) at day 10 (Figure 4D). Therefore, to determine whether MAIT cells located in the lymph nodes traffic to the lungs during LVS IN infection, mice were administered the sphingosine-1-phosphate receptor agonist FTY720. FTY720 (fingolimod) is an FDA-approved drug for multiple sclerosis that inhibits lymphocyte egress from the thymus and secondary lymphoid organs (38). Mice were treated with FTY720 starting on day 2 after LVS IN infection, before MAIT cells increased significantly in the lungs, and daily administration was continued until we investigated the numbers of MAIT cells, CD4\(^{+}\) T cells, and CD8\(^{+}\) T cells in the lungs on day 10. As shown in Figure 4E, the numbers of CD4\(^{+}\) and CD8\(^{+}\) T cells were significantly reduced in the lungs of mice administered FTY720 as compared to control mice, indicating that a large proportion of these T cells trafficked to the lungs from secondary lymphoid organs. In contrast, the number of MAIT cells in the lungs of mice administered FTY720 was not significantly different from control mice, demonstrating that emigration from the lymph nodes and other secondary lymphoid organs does not substantially contribute to the MAIT cell population found in the lungs during infection. This evidence, coupled with the high levels of BrdU incorporated by lung MAIT cells after IN administration, suggest that the majority of MAIT cells in the lungs during pulmonary infection arise from \textit{in situ} proliferation as opposed to trafficking from other sites.

### Intranasal Administration of CXCL16 and 5-OP-RU Induces MAIT Cell Accumulation in the Lungs Under Non-inflammatory Conditions

Previous studies have shown that intranasal administration of a TLR agonist (e.g., CpG, Pam\(_3\)CSK\(_4\)) and a MAIT cell activating antigen (e.g., 5-OP-RU) induced robust accumulation of MAIT cells in the lungs of naïve mice (10). In contrast, intranasal inoculation of a TLR agonist in combination with the MAIT cell inhibitory antigen Ac-6-FP failed to stimulate...
FIGURE 4 | MAIT cells are not recruited from secondary lymphoid organs and largely proliferate in situ in the lungs during *F. tularensis* LVS pulmonary infection. (A) Representative flow cytometry dot plots of MAIT cells (gated on live 5-OP-RU MR1 tetramer^+^ TCRβ^+^ cells) in the lungs of WT mice on days 6–10 after LVS IN (Continued)
MAIT cell accumulation. Further, the TLR agonist and the MAIT cell antigen were both essential, as administration of either component individually was not sufficient to increase MAIT cell numbers in the lungs. TLR agonists are highly immunostimulatory and thus far it remains unclear which of the many cytokines and chemokines produced in response to these agents are sufficient to induce MAIT cell accumulation in combination with 5-OP-RU.

Although our data show that CXCR6 is not required to increase MAIT cell numbers in the lungs during the peak of infection, this does not rule out a redundant role for the CXCR6/CXCL16 axis in MAIT cell accumulation. Since the majority of MAIT cells expressed CXCR6, we next sought to determine whether administration of CXCL16 might be sufficient to replace the aforementioned TLR agonists in the promotion of MAIT cell accumulation when combined with 5-OP-RU. To this end, recombinant CXCL16 and 5-OP-RU were administrated intranasally to naïve WT mice on day 1, and 5-OP-RU alone was administrated intranasally on days 2 and 3. MAIT cell numbers in the lungs on day 7 were then compared to several different control immunostimulatory combinations (Figures 5A,B). Consistent with previous research (10), the TLR2/6 agonist Pam2CSK4 + 5-OP-RU dramatically induced MAIT cell accumulation in the lungs (7.5 ± 0.1% of total lung cells). Significant accumulation of MAIT cells was also observed in mice that received CXCL16 + 5-OP-RU (3.7 ± 0.7%) on days 1, 2, and 3, but not in those that received CXCL16 + Ac-6-FP (0.4 ± 0.1%) or PBS (0.2 ± 0.02%) (Figures 5A,B). Recombinant CCL24 and heat denatured CXCL16 were used as controls to confirm the role of CXCL16 in the enrichment of MAIT cells. CCL24 binds the chemokine receptor CCR3, which is crucial for directing migration and priming of eosinophils and is unlikely to contribute to MAIT cell trafficking (39). When CCL24 + 5-OP-RU (0.6 ± 0.2%) or heat-denatured CXCL16 + 5-OP-RU (0.6 ± 0.1%) were administrated intranasally to naïve WT mice (Figures 5A,B), no significant MAIT cell accumulation was observed. Of note, mice treated with CXCL16 + 5-OP-RU did not exhibit significant differences in the numbers of conventional CD4+ and CD8+ T cells or inflammatory monocytes (Ly6Chi CD11b+ ) as compared to mice given PBS (Figure S4). In contrast, mice administered CXCL16 + 5-OP-RU exhibited significantly more antigen presenting cells (CD11c+ MHCII+) as compared to PBS-treated mice, but not CXCL16 + Ac-6-FP-treated mice, indicating that this effect was not related to MAIT cell accumulation (Figure S4). Overall, these data demonstrate that CXCL16 in combination with 5-OP-RU is sufficient to induce MAIT cell accumulation in vivo.

To assess the ability of CXCL16 and CXCL16 + 5-OP-RU to stimulate MAIT cell cytokine production, purified transgenic murine MAIT cells were co-cultured with uninfected macrophages (for antigen presentation), recombinant CXCL16, and 5-OP-RU. As shown in Figure 5C, 5-OP-RU alone stimulated MAIT cells to produce multiple cytokines, including TNF, IL-17A, IL-22, GM-CSF, and IFN-γ. In contrast, CXCL16 alone failed to stimulate MAIT cell cytokine production. MAIT cells stimulated with the combination of CXCL16 + 5-OP-RU did not exhibit a significant increase in cytokine production as compared to those treated with 5-OP-RU alone. These data show that MAIT cells respond to CXCL16 + 5-OP-RU by producing critical cytokines, but that CXCL16 does not significantly augment the levels of MAIT cell effector cytokines produced in response to 5-OP-RU alone.

**DISCUSSION**

The chemokine receptor CXCR6 was originally described as the HIV and SIV co-receptor (40–42) and is expressed on NKT cells, a subset of activated T cells, and some NK cells (43–45). CXCR6 and its ligand CXCL16 have been shown to mediate homing of lymphocytes to non-lymphoid tissues as well as NK T cell homeostasis and activation (43, 45–48). Since several studies have shown that MAIT cells also express CXCR6 (21, 25), we were interested in determining its role in MAIT cell trafficking, cytokine production, and tissue localization.

Using the *F. tularensis* LVS pulmonary infection model, we found that the vast majority of MAIT cells in the lungs expressed CXCR6 during infection. Despite this finding, CXCR6 was not required for accumulation of MAIT cells in either the lung parenchyma or the airway lumen during LVS infection. Similarly, MAIT cell production of IFN-γ, TNF, and IL-17A was not significantly affected in CXCR6−/− mice. Interestingly, however, CXCR6 had a significant role in maintaining MAIT cells in the airway lumen long after clearance of LVS infection. Importantly, CXCL16 is expressed in both soluble and membrane-bound forms (49), with the latter inducing adhesion of cells expressing CXCR6 (50). This is consistent with findings that suggest CXCL16 is weakly...
Intranasal instillation of CXCL16 and 5-OP-RU induces MAIT cell accumulation in the lungs in the absence of infection. Naïve WT mice were intranasally administered 5-OP-RU or control Ac-6-FP (6-FP) with one of the chemokines shown on days 1, 2, and 3. Mice given 5-OP-RU + Pam were intranasally administered 5-OP-RU and Pam on day 1, and 5-OP-RU alone on days 2 and 3. On day 7, the lungs were harvested for flow cytometry analysis. “PBS” mice received only PBS at the indicated time points. (A) Representative flow cytometry dot plots showing 5-OP-RU MR1 tetramer$^\text{+}$ TCR$^\beta$+ MAIT cells in naïve WT mice treated as indicated. Total live singlet lung cells for individual mice are shown. (B) A graphical representation of the number of MAIT cells in the lungs on day 7 (**P < 0.001). (C) Vα19TgMR1$^{+/+}$ transgenic murine MAIT cells were co-cultured with uninfected macrophages, recombinant CXCL16, and 5-OP-RU, and cytokine production was measured after 16 h. “No stimulation” = uninfected macrophages and MAIT cells. hd CXCL16 = heat-denatured CXCL16, Pam = Pam$\text{2}_\text{CSK}_{4}$. Data are presented as the mean ± SEM (n = 3) and is representative of three independent experiments.

chemotactic (51) and instead has a role in controlling the localization of CXCR6$^+$ cells within different compartments of the lung rather than directly recruiting them from the circulation (35). Indeed, CXCL16 is constitutively expressed by bronchial epithelial cells, which could facilitate retention of T lymphocytes in the lungs (35, 40, 52). Our own data identified CXCL16 as being up-regulated in the lungs during LVS infection and remained significantly elevated even after the bacterial CFUs had fully cleared. Overall, our data show that CXCR6 is not required for MAIT cell recruitment during infection but instead supports long-term retention of MAIT cells in the airway lumen.
Although our data does not rule out a role for chemokine receptors in MAIT cell recruitment, it raised the question of whether MAIT cells proliferate in situ in the lungs during pulmonary LVS infection. Of particular interest, Wang et al. found that MAIT cells in both the lungs and mediastinal lymph nodes proliferated during pulmonary Legionella longbeachae infection (11). This study delivered BrdU via the intraperitoneal route and used a short labeling period (2 h) to avoid detecting cells that had proliferated elsewhere and migrated to the lungs. In our study, we delivered BrdU directly to the lungs by intranasal instillation and investigated the possibility that MAIT cells migrate from secondary lymphoid organs during infection. We found that the majority of MAIT cells in the lungs (∼60%) and a smaller proportion in the lung-draining lymph nodes (∼15%) incorporated BrdU during LVS pulmonary infection. Further, MAIT cell accumulation in the lungs was not impacted by treatment with the sphingosine-1-phosphate agonist FTY720, which inhibits lymphocyte trafficking from the thymus and secondary lymphoid organs (38). This was in sharp contrast to conventional CD4+ and CD8+ T cells, which exhibited impaired recruitment to the lungs after FTY720 treatment. Although FTY720 does not inhibit the migration of T cells found in non-lymphoid tissues and the blood, our combined data suggest that the majority of MAIT cells in the lungs arise from in situ proliferation during infection.

Several studies have demonstrated that MAIT cell accumulation in the lungs can be induced by intranasal instillation of a TLR agonist and a MAIT cell antigen in naïve mice (10, 53). Since TLR agonists stimulate production of multiple cytokines and chemokines, the precise agents that facilitate MAIT cell accumulation remain unknown. Further, TLR agonists are broadly inflammatory and may be detrimental in some situations where MAIT cells could be targeted as an immunotherapy. Here we found that intranasal administration of CXCL16 with 5-OP-RU was sufficient to increase MAIT cell numbers in the lungs of naïve mice, although it was not as effective as the TLR agonist Pam3CSK4. This is similar to the finding that intranasal delivery of the Mycobacterium tuberculosis antigen rec85A with CXCL16 induced enrichment of antigen-specific CXCR6+ T cells in the airways of previously immunized mice and provided significant protection against pulmonary M. tuberculosis infection (54). Although our data showed that CXCR6 was not essential for MAIT cell recruitment during LVS infection, this does not rule out a non-redundant role for the CCR6/CXCL16 axis in MAIT cell accumulation. However, it is particularly interesting to note that CXCL16 stimulated proliferation of Jurkat T cells and primary human CD4+ T cells in vitro (55). In this light, it is possible that CXCL16 in combination with 5-OP-RU stimulated MAIT cell proliferation rather than recruitment to the lungs. Overall, our data demonstrate that CXCL16 can partially replace TLR agonists in regimens used to induce MAIT cell accumulation, offering a more targeted method to achieve this goal.

In summary, here we found that the vast majority of MAIT cells were CXCR6+ during pulmonary F. tularensis LVS infection, but that CXCR6 was not required for MAIT cell accumulation in the lung parenchyma. However, CXCR6 contributed to long-term retention of MAIT cells in the airway lumen. Our data show that MAIT cells are not recruited from secondary lymphoid tissues and largely proliferate in situ in the lungs during infection. Importantly, we found that CXCL16 can partially substitute for TLRs in therapeutic regimens that induce MAIT cell accumulation via administration of 5-OP-RU. Overall, our data advance the understanding of the mechanisms that facilitate MAIT cell accumulation and retention in the tissues.

DATA AVAILABILITY STATEMENT

All datasets presented in this study are included in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by FDA White Oak Animal Care and Use Committee.

AUTHOR CONTRIBUTIONS

SC and HY designed the study and analyzed and interpreted data. HY and AY performed experiments. LL, JM, and DF provided reagents. SC, HY, LL, JM, and DF wrote the manuscript. All authors contributed to the article and approved the submitted version.

FUNDING

This work was funded by internal Center for Biologics Evaluation and Research/Food and Drug Administration (U.S. government) operating funds. We thank the Australian Research Council for a Center of Excellence in Advanced Molecular Imaging Grant No. CE140100011.

ACKNOWLEDGMENTS

The authors are grateful to Dr. Ted Hansen for providing the MR1−/− and Vα19I transgenic mice, as well as Dr. Akue and Dr. Kukuruga in the FDA flow cytometry core facility for flow cytometry service. LL and DF were inventors on patent application (PCT/AU2013/000742, WO2014005194), while LL, JM, and DF were inventors on patent application (PCT/AU2015/050148, WO2015149130).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01773/full#supplementary-material
REFERENCES

1. Meierovic AI, Cowley SC. MAIT cells promote inflammatory monocyte differentiation into dendritic cells during pulmonary intracellular infection. J Exp. Med. (2016) 213:2793–809. doi: 10.1084/jem.20160637
2. Gold MC, Cerri S, Smyk-Pearson S, Cansler ME, Vogt TM, Delepine J, et al. Human mucosal associated invariant T cells detect bacterially infected cells. PLoS Biol. (2010) 8:e1000407. doi: 10.1371/journal.pbio.1000407
3. Le Bourhis L, Dusseaux M, Bohineust A, Bessoles S, Martin E, Premel V, et al. MAIT cells detect and efficiently lyse bacteriologically infected epithelial cells. PLoS Pathog. (2013) 9:e1003681. doi: 10.1371/journal.ppat.1003681
4. Sakala IG, Kjer-Nielsen L, Eckhoff CS, Wang X, Blazevic A, Liu L, et al. Functional heterogeneity and antimicrobial effects of mouse mucosal-associated invariant T cells specific for riboflavin metabolites. J Immunol. (2015) 195:587–601. doi: 10.4049/jimmunol.1402545
5. Patel O, Kjer-Nielsen L, Le Nours J, Eckle SB, Beddoe T, et al. Recognition of vitamin B metabolites by mucosal-associated invariant T cells. Nat Commun. (2013) 4:2142. doi: 10.1038/ncomms3142
6. Corbett AJ, Eckle SB, Birkinshaw RW, Liu L, Patel O, Mahony J, et al. T-cell activation by transitory neo-antigens derived from distinct microbial pathways. Nature. (2014) 509:361–5. doi: 10.1038/nature13160
7. Kjer-Nielsen L, Patel O, Corbett AJ, Le Nours J, Meehan B, Liu L, et al. MR1 presents microbial vitamin B metabolites to MAIT cells. Nature. (2012) 491:717–23. doi: 10.1038/nature11605
8. Eckle SB, Corbett AJ, Keller AN, Chen Z, Godfrey DL, Liu L, et al. Recognition of vitamin B precursors and byproducts by mucosal associated invariant T cells. J Biol Chem. (2010) 285:30204–11. doi: 10.1074/jbc.R110.851990
9. Meierovic A, Yankelevich WJ, Cowley SC. MAIT cells are critical for optimal mucosal immune responses during in vivo pulmonary bacterial infection. Proc Natl Acad Sci USA. (2013) 110:ES119–28. doi: 10.1073/pnas.1302799110
10. Chen Z, Wang H, D’Souza C, Sun S, Kostoien L, Eckle SB, et al. Mucosal-associated invariant T-cell activation and accumulation after in vivo infection depends on microbial riboflavin synthesis and co-stimulatory signals. Mucosal Immunol. (2017) 10:58–68. doi: 10.1038/mi.2016.39
11. Wang H, D’Souza C, Lim XY, Kostenko L, Pediongco TJ, Eckle SBG, et al. MAIT cells protect against pulmonary legionella longbeachiae infection. Nat Commun. (2018) 9:3350. doi: 10.1038/s41467-018-05202-8
12. Willing A, Leach OA, Ufer F, Attfield KE, Steinbach K, Kursawe N, et al. CD8(+) MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosis. Eur J Immunol. (2014) 44:1129–38. doi: 10.1002/eji.201341460
13. Serriari NE, Eoche M, Lamotte L, Lion J, Fumery M, Marcelo P, et al. Innate immune responses in the human airway epithelium after influenza infection. J Immunol. (2014) 192:6266–74. doi: 10.1111/j.1523-1747.2014.04227.x
14. Petersone L, Walker LSK. MAIT cells in type 1 diabetes: a good friend turned bad. Nat Immunol. (2017) 18:1283–5. doi: 10.1038/ni.3869
15. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. (2005) 23:127–59. doi: 10.1146/annurev.immunol.23.021704.115628
16. Baggilolini M. Chemokines and leukocyte traffic. Nature. (1998) 392:565–8. doi: 10.1038/33340
17. Kim CH, Brxomeyer HE. Chemokines: signal traps for trafficking of T and B cells for development and effector function. J Leukoc Biol. (1999) 65:6–15. doi: 10.1002/jlb.65.1.6
18. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokine grammar for immune cells. Annu Rev Immunol. (2004) 22:891–928. doi: 10.1146/annurev.immunol.22.021703.104543
19. Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. (2012) 36:705–16. doi: 10.1016/j.immuni.2012.05.008
20. Martin E, Treiner E, Duban L, Guerru L, Laude H, Toly C, et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol. (2009) 7:e54. doi: 10.1371/journal.pbio.1000054
21. Dusseaux M, Martin E, Serriari N, Peggullit I, Premel V, Louis D, et al. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. (2011) 117:1250–9. doi: 10.1182/blood-2010-08-30339
22. Fergusson JR, Huhn MH, Swadling L, Walker LJ, Kurioka A, Llibre A, et al. CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol. (2016) 9:401–13. doi: 10.1038/mi.2015.69
23. Tang XZ, Jo J, Tan AT, Sandalova E, Chia A, Tan KC, et al. IL-7 licenses activation of human liver intrasinusoidal mucosal-associated invariant T cells. J Immunol. (2013) 190:3142–52. doi: 10.4049/jimmunol.120218
24. Koay HF, Gheuernin NA, Enders A, Loh L, Mackay LK, Almeida CF, et al. A three-stage intrathymic development pathway for the mucosal-associated invariant T cell lineage. Nat Immunol. (2016) 17:1300–11. doi: 10.1038/ni.3565
25. Rahimpour A, Koay HF, Enders A, Clancy R, Eckle SB, Meehan B, et al. Identification of phenotypically and functionally heterogeneous mouse mucosal-associated invariant T cells using MR1 tetramers. J Exp. Med. (2015) 212:1095–108. doi: 10.1042/jem142110
26. Mack JY, Xu W, Reid RC., Corbett AJ, Mehan BS, Wang H, et al. Stabilizing short-lived Schiff base derivatives of S-aminouracils that activate mucosal-associated invariant T cells. Nat Commun. (2017) 8:14599. doi: 10.1038/ncomms14599
27. Cowley SC, Elkins KL. Multiple T cell subsets control Francieilla tularensis LVS intracellular growth without stimulation through macrophage interferon gamma receptors. J Exp. Med. (2003) 198:379–89. doi: 10.1084/jem.20030687
28. Treiner E, Duban L, Bahram S, Radosavljevic M, Wanner V, Tilloy E, et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature. (2003) 422:164–9. doi: 10.1038/nature01433
29. Kawachi I, Maldonado J, Strader C, Gilfillan S, Meehan BS, Wang H, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. (2000) 275:40663–6. doi: 10.1074/jbc.C000761200
30. Matsunaga J, Matsumoto A, Omura E, Neufeld B, Huang D, Imai K, et al. Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages. J Biol Chem. (2003) 278:1005–10. doi: 10.1074/jbc.C000761200
31. Mak JY, Xu W, Reid RC, Corbett AJ, Meehan BS, Wang H, et al. Stabilizing short-lived Schiff base derivatives of S-aminouracils that activate mucosal-associated invariant T cells. Nat Commun. (2017) 8:14599. doi: 10.1038/ncomms14599
41. Liao F, Alkhatib G, Peden KW, Sharma G, Berger EA, Farber JM. STRL33, a novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1. J Exp Med. (1997) 185:2015–23. doi: 10.1084/jem.185.11.2015

42. Deng HK, Unutmaz D, KewalRamani VN, Littman DR. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. (1997) 388:296–300. doi: 10.1038/40894

43. Geissmann F, Cameron TO, Siodobre S, Manlongat N, Kronenberg M, Briskin MJ, et al. Intravascular immune surveillance by CXCR6+NKT cells patrolling liver sinusoids. PLoS Biol. (2005) 3:e113. doi: 10.1371/journal.pbio.0030113

44. Sato T, Thorlacius H, Johnston B, Staton TL, Xiang W, Littman DR, et al. Role for CXCR6 in recruitment of activated CD8+ lymphocytes to inflamed liver. J Immunol. (2005) 174:277–83. doi: 10.4049/jimmunol.174.1.277

45. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genoves e MC, et al. Bonzo/CXCR6 expression defines type 1-polarized T-cell subsets with extralymphoid tissue homing potential. J Clin Invest. (2001) 107:595–601. doi: 10.1172/JCI11902

46. Alkhatib G, Ahuja SS, Light D, Mummidii S, Berger EA, Ahuja SK. CC chemokine receptor 5-mediated signaling and HIV-1 Co-receptor activity share common structural determinants. Critical residues in the third extracellular loop support HIV-1 fusion. J Biol Chem. (1997) 272:19771–6. doi: 10.1074/jbc.272.32.19771

47. Jiang X, Shimaoka T, Kojo S, Harada M, Watarai H, Wakao H, et al. Cutting edge: critical role of CXCL16/CXCR6 in NK cell trafficking in allotransplantation. J Immunol. (2005) 175:2051–5. doi: 10.4049/jimmunol.175.4.2051

48. Germanov E, Vezinotte L, Cullen R, Chamberlain E, Butcher EC, Johnston B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. J Immunol. (2008) 181:81–91. doi: 10.4049/jimmunol.181.1.81

49. Bazan JE, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, et al. A new class of membrane-bound chemokine with a CX3C motif. Nature. (1997) 385:640–4. doi: 10.1038/385640a0

50. Shimaoka TA, Nakayama T, Fukumoto N, Kume N, Takahashi S, Yamaguchi J, et al. Cell surface-anchored SR-PSOX/CXC chemokine ligand 16 mediates firm adhesion of CXC chemokine receptor 6-expressing cells. J Leukoc Biol. (2004) 75:267–74. doi: 10.1189/jlb.1003465

51. Latta M, Mohan K, Iseki kutz TB. CXCR6 is expressed on T cells in both T helper type 1 (Th1) inflammation and allergen-induced Th2 lung inflammation but is only a weak mediator of chemotaxis. Immunology. (2007) 121:555–64. doi: 10.1111/j.1365-2567.2007. 02603.x

52. Day C, Patel R, Guillen C, Wardlaw AJ. The chemokine CXCL16 is highly and constitutively expressed by human bronchial epithelial cells. Exp Lung Res. (2009) 35:272–83. doi: 10.1080/01902140802635517

53. Ussher JE, van Wilgenburg B, Hannaway RF, Ruustal K, Phalora P, Kurioka A, et al. TLR signaling in human antigen-presenting cells regulates MR1-dependent activation of MAIT cells. Eur J Immunol. (2016) 46:1600–14. doi: 10.1002/eji.201545969

54. Lee LN, Ronan EO, de Lara C, Franken KL, Ottenhoff TH, Tchilian EZ, et al. CXCR6 is a marker for protective antigen-specific cells in the lungs after intranasal immunization against Mycobacterium tuberculosis. Infect Immun. (2011) 79:3328–37. doi: 10.1128/IAI.01133-10

55. Darash-Yahana M, Gillespie JW, Hewitt SM, Chen YY, Maeda S, Stein I, et al. The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers. PLoS ONE. (2009) 4:e6695. doi: 10.1371/journal.pone.0006695

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Yu, Yang, Liu, Mak, Fairlie and Cowley. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.